Vici syndrome is a recessively inherited multisystem disorder characterized by callosal agenesis, cataracts, cardiomyopathy, combined immunodeficiency and hypopigmentation. To investigate the molecular basis of Vici syndrome, we carried out exome and Sanger sequence analysis in a cohort of 18 affected individuals. We identified recessive mutations in EPG5 (previously KIAA1632), indicating a causative role in Vici syndrome. EPG5 is the human homolog of the metazoanspecific autophagy gene epg-5, encoding a key autophagy regulator (ectopic P-granules autophagy protein 5) implicated in the formation of autolysosomes. Further studies showed a severe block in autophagosomal clearance in muscle and fibroblasts from individuals with mutant EPG5, resulting in the accumulation of autophagic cargo in autophagosomes. These findings position Vici syndrome as a paradigm of human multisystem disorders associated with defective autophagy and suggest a fundamental role of the autophagy pathway in the immune system and the anatomical and functional formation of organs such as the brain and heart.
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Vici syndrome (MIM 242840) 1 is a rare multisystem disorder characterized by callosal agenesis, cataracts, cardiomyopathy, combined immunodeficiency and hypopigmentation. Its occurrence in consanguineous families and siblings suggests recessive inheritance [1] [2] [3] [4] [5] [6] .
We identified 18 individuals with Vici syndrome of European (n = 11), Arab (n = 3), Turkish (n = 2), Japanese (n = 1) and British-Asian origin (n = 1), 9 of whom were previously reported 1, [4] [5] [6] [7] [8] [9] . Clinical findings from these individuals are summarized in Supplementary  Table 1 and depicted in Supplementary Figure 1 .
Muscle biopsies available from eight affected individuals showed consistent myopathic features 5, 6 , comprising fiber-type disproportion with type 1 atrophy, increase in internal nuclei and abnormal glycogen accumulation (data not shown). On electron microscopy images ( Fig. 1) , there was redundancy of basal lamina, with material between layers, suggesting exocytosis of debris. There were numerous vacuole-like areas and dense bodies, possibly of lysosomal origin. Myofibrils were lacking in many fibers. Mitochondria were of variable size and showed abnormal distribution and morphology.
We sequenced the exomes of four individuals with Vici syndrome from three families, one multiplex consanguineous family and two non-consanguineous families with one affected child each, and identified only one gene, EPG5 (NM_020964.2; previously KIAA1632) on chromosome 18q12.3 in which we found mutations in all affected individuals. Analysis of all EPG5 coding exons in a total of 15 families l e t t e r s with Vici syndrome with 18 affected individuals showed homozygosity or compound heterozygosity for truncating mutations (including mutations affecting the invariant splice donor and acceptor recognition sites) in 10 individuals and compound heterozygosity for truncating and missense mutations in 2 families. Subject 7.1 was homozygous for a mutation affecting the penultimate base of exon 2, predicted to cause aberrant splicing ( Table 1) . Parental studies suggested recessive inheritance with no carrier manifestations. Subjects 14.1 and 15.1 did not have any pathogenic sequence variants; quantitative fluorescent PCR (QF-PCR) did not identify any copy-number variations in subject 14.1. Although the absence of EPG5 mutations in these individuals indicates the possibility of locus heterogeneity (supported by the presence of heterozygous SNPs in EPG5 in subject 14.1, who comes from a consanguineous partnership), we cannot exclude the possibility of splice-site or promoter variants or mutations affecting other regulatory elements. Sequencing of VMP1 (NM_030938.3) and EI24 (NM_004879.3), the human homologs of C. elegans epg-3 and epg-4, respectively, identified by Tian et al. 10 , did not reveal any mutations.
EPG5 consists of 44 exons, encodes a protein of 2,579 amino acids 11 and is predominantly expressed in the central nervous system (CNS), skeletal and cardiac muscle, thymus, immune cells, lung and kidneys. EPG5 is the human homolog of epg-5 in Caenorhabditis elegans, which encodes a protein with a key role in the autophagy pathway of multicellular organisms 10 . EPG5 has previously been found to be mutated in human cancer tissue 12 , a finding shared with other genes implicated in the autophagy machinery 13 .
Autophagy is an evolutionarily highly conserved lysosomal degradation pathway with fundamental roles in cellular homeostasis, including nutrient provision during fasting or increased metabolic demands, removal of defective proteins or organelles, and defense against infection [14] [15] [16] [17] [18] [19] . A role in normal embryonic development has been suggested 20 and is supported by the recent observation of a link between autophagy and early differentiation events in human embryonic stem cells 21 . Autophagy has also emerged as a key regulator of cardiac and skeletal muscle homeostasis and functional remodelling [22] [23] [24] . The process of autophagy involves several tightly regulated steps: (i) formation of an isolation membrane (the phagophore), (ii) fusion of the phagophore to form a doublemembranated autophagosome and (iii) fusion of the autophagosome with a lysosome to form the autolysosome, where both captured membrane and contents are degraded. Defects in the autophagy pathway can be broadly divided into those causing impaired autophagosome formation and those causing decreased autolysosome clearance. npg l e t t e r s
Membrane dynamics during autophagy are highly conserved from yeast to mammals, but, along the evolutionary trajectory, they involve an increasingly complex molecular machinery. In yeast, a set of more than 30 ATG (autophagy-related) genes encode proteins involved in the autophagic cascade 18 ; this conserved group is modulated in higher organisms by mammalian-specific factors, mainly with a role in autophagosome-lysosome fusion. Epg-5 is one of four higher eukaryote-specific autophagy genes in C. elegans (in addition to epg-2, epg-3 and epg-4), which regulate specific autophagy steps in multicellular organisms and are ubiquitously expressed in early development 10 . Epg-3, Epg-4 and Epg-5 have an important role in starvation-induced autophagy, as suggested by the reduced survival of animals with mutations in these genes in the absence of food. Epg-5 seems to be specifically involved in a late step of autophagy, the autophagic degradation of protein aggregates, as evidenced by defects in phagolysosome formation in the absence of Epg-5 (ref. 25 ), accumulation of non-degradative autolysosomes following knockdown of mammalian EPG5 in HeLa cells and accelerated autophagic degradation following epg-5 overexpression 10 .
To further investigate the autophagy pathway in Vici syndrome, we performed additional immunofluorescence studies on skeletal muscle tissue from two affected individuals (subjects 2.1 and 3.1). We observed marked fiber atrophy and fiber size heterogeneity with upregulation of the sarcomere-associated autophagy proteins SQSTM1 (p62) and NBR1 (refs. 26-28) ( Fig. 2) , with numerous positive puncta (autophagosomes) in many fibers compared to normal controls that were also positive for LC3 but not for sarcomeric proteins. The same fibers also showed strong upregulation of MURF2, a SQSTM1-linked muscle ubiquitin E3 ligase 29 . Immunofluorescence microscopy and analysis of electron microscopy images detected no obvious myofibrillar abnormalities, in contrast to the secondary autophagy defects due to mutations in BAG3 (ref. 30) or the kinase domain of titin 26, 31 . This suggests that EPG5 may not be involved in the autophagic degradation of myofibrillar components.
We hypothesized that the increases in SQSTM1 and NBR1 in atrophic muscle fibers reflect a block in the autophagy pathway, in keeping with the accumulation of autolysosomes observed after epg-5 knockdown in multicellular organisms 10 and the observation of severe muscle atrophy and cardiac failure following autophagy inhibition 22, 32, 33 . To further investigate whether the increased SQSTM1 and NBR1 levels are reflective of increased upstream induction or downstream blockade of the autophagy pathway, we exposed fibroblasts derived from affected individuals and healthy controls for 12 h to the autophagy inducer rapamycin (an inhibitor of the mTORC1 complex) and the autophagy inhibitor bafilomycin (an inhibitor of the autolysosomal H + ATPase required for acidification and, hence, degradation of lysosomal contents 34 ). Untreated cells from affected individuals showed higher amounts of SQSTM1, NBR1 and LC3, particularly of processed, lipidated LC3-II. Induction of autophagy by rapamycin or blockade of autophagosomal clearance by bafilomycin led to strong accumulation of NBR1 and SQSTM1 in control cells after 12 h, whereas the combination of upstream activation by rapamycin and blockade of clearance by bafilomycin led to further accumulation of these proteins as well as of LC3-II after 12 h ( Fig. 3) , as expected. In contrast, the higher amounts of NBR1 and SQSTM1 were not further increased in cells from individuals with Vici syndrome after treatment with rapamycin or combination treatment. This suggests that the induction of early steps in autophagy, including the processing of LC3-I to LC3-II, is not impaired in Vici syndrome, whereas the clearance of autophagosomal cargo is severely impaired. These observations are supported by immunofluorescence microscopy in fibroblasts from individuals with Vici syndrome: we observed a large number of baseline NBR1-and SQSTM1-positive puncta ( Supplementary Fig. 2 ) as well as LC3-and SQSTM1-positive puncta ( Supplementary  Fig. 3 ) compared to control cells, indicative of the accumulation of autophagosomes in the EPG5-deficient cells. In contrast, we found that the fusion of LC3-positive puncta with lysosomes, as indicated by the colocalization of LC3 with lysosome-associated membrane proteins (LAMP1), was reduced in fibroblasts from individuals with Vici syndrome (Fig. 4) . Similarly, there was much less fusion of NBR1-positive puncta with LAMP1-positive lysosomal vesicles ( Supplementary Fig. 4) . Lastly, baseline amounts of protein polyubiquitinated at lysine 63 (a measure of ubiquitination products Figure 3 Autophagy is blocked at a late stage in Vici syndrome. Accumulation of autophagy adaptors NBR1 and SQSTM1 and the phagophore membrane component LC3 is induced in fibroblasts from two controls and a subject with Vici syndrome (subject 4.1) after 12 h of treatment with rapamycin or dual treatment with rapamycin and bafilomycin.
npg l e t t e r s destined for autolysosomal degradation) were higher in cells from individuals with Vici syndrome (Supplementary Fig. 5 ). Taken together, these results indicate a severe deficit in autophagosomal clearance associated with mutations in EPG5, which results in the accumulation of autophagic cargo in NBR1-and SQSTM1-positive autophagosomes and impaired fusion with lysosomes.
To determine whether these changes also involve upstream regulatory mechanisms of autophagy, we analyzed the AKT-mTOR protein kinase pathway, a major pathway controlling the expression of autophagy proteins, by inhibiting the transcriptional activity of FOXO transcription factors 35 . We observed markedly lower phosphorylation of the two activating sites in AKT (Ser308 and Ser473) and, as a result, lower phosphorylation of the AKT substrate GSK-3β on the inhibitory Ser21 site (Supplementary Fig. 6 ). Whereas total FOXO3 protein amounts were about 5-fold higher, the ratio of phosphorylated to total FOXO was decreased to about 0.6 ( Supplementary Fig. 7) . These observations suggest a profound derailment of autophagy in Vici syndrome on multiple regulatory levels, including transcriptional regulation via the AKT pathway.
These findings are all in agreement with histopathological features consistent with defective autophagy, such as the prominence of autophagic vacuoles, storage of abnormal material and secondary mitochondrial abnormalities, the latter of which likely reflects the evolutionarily conserved role of the autophagy pathway in maintaining mitochondrial quality and function 36 . On the clinical level, skeletal and cardiac muscle involvement also features prominently in other conditions with primary disturbance of autophagy, such as X-linked recessive Danon disease (MIM 300257), caused by abnormal autolysosome formation due to mutations in the lysosomal LAMP-2 gene 37 . Disrupted autophagy is also an important secondary pathogenetic mechanism in other neuromuscular disorders 26, [38] [39] [40] . In the heart, autophagy has an important role in the constant renewal of postmitotic cardiomyocytes 41 and functions to meet nutrient requirements at times of increased metabolic demand 42, 43 . Of note, microscopic cardiac changes observed post mortem in one individual with Vici syndrome were much more pronounced in the left compared to the right ventricle 9 , suggesting a relationship between the intensity of physiological workload and the severity of histopathological changes.
Additional defects in CNS development, immune regulation and skin pigmentation in individuals with Vici syndrome implicate autophagy in a wider range of cellular processes. In the brain, autophagy has been extensively investigated as a key pathogenic mechanism in various neurodegenerative disorders (for reviews, see refs. 17, 44) . The observation of callosal agenesis and disturbed neuromigration in individuals with Vici syndrome identifies aberrant autophagy also as a cause of disturbed embryonic CNS development, a notion so far only supported by the observation of increased neuronal proliferation and severe neural tube defects in mice with null mutations in Ambra1, a positive autophagy regulator with predominant expression in neural tissues 45 . In the immune system, autophagy is generally involved in the delivery of microorganisms to lysosomes (xenophagy) and, more specifically, in trafficking events that activate immunity 46 . As indicated by observations in the T cellspecific Atg5-knockout mouse, autophagy is directly important for T-cell survival and proliferation 47 , and our findings also indicate a role for autophagy in B-cell homeostasis. The finding of generalized hypopigmentation in Vici syndrome supports a functional relationship between melanogenesis and the autophagic machinery, as has been suggested recently 48 .
In conclusion, our findings identify Vici syndrome as a paradigm for human multisystem disorders associated with defective autophagy. The wide range of associated clinical manifestations suggests that EPG5 is a pivotal protein within the autophagic machinery in different tissues. Other genes within the same pathway are plausible candidates in Vici syndrome cases not linked to the EPG5 locus. 
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Solution capture. Solution capture was carried out according to Agilent's v.1.0.1 protocol with the following modifications: 500 ng of prepped library were mixed with 7.5 µg of human Cot-1 DNA and dried down to a pellet using a Savant SpeedVac 120 (Thermo Fisher Scientific). The pellet was resuspended in 3.4 µl of water to give a final library concentration of 147 ng/µl. After hybridization and selection, libraries were subjected to ten cycles of PCR amplification.
Sequencing. Target-enriched sequencing libraries were quantified by Qubit (Invitrogen). Denatured libraries were loaded onto an Illumina Genome Analyzer IIx flow cell at a concentration of 10 pM.
Sequencing of flow cells was carried out as described in the manufacturer's instructions, using one lane of 76-bp paired-end sequencing per sample.
Read conversion and alignment. Read conversion, alignment and variant calling were conducted in parallel using both the NextGENe (SoftGenetics) and Linux-based tools on the King's College London (KCL) cluster as follows. Sequencing metrics are described in Supplementary Table 2 .
NextGENe read conversion and alignment. Reads were obtained in qseq format from the Genome Analyzer IIx instrument. NextGENe software was used to quality filter and convert the reads into fasta format. The following filtering settings were used: median phred score of 15, maximum number of uncalled bases of 10, called base number greater than or equal to 25, and trim or reject reads where 10 or more bases have a phred score of 15 or less. Reads not fulfilling these quality criteria were omitted from alignment.
Quality-filtered fasta-converted reads were aligned to the whole human genome reference sequence (GRCh37) using the preindexed reference in NextGENe.
KCL Linux alignment. Sequence reads were aligned to the reference genome (hg18) with Novoalign (see URLs). Duplicate reads, resulting from PCR clonality or optical duplicates, and reads mapping to multiple locations were excluded from downstream analysis. Single-nucleotide substitutions and small insertions or deletions were identified and quality filtered within the SAMtools software package 49 and in-house software tools. Variants were annotated with respect to genes and transcripts with the SNPClassifier tool 50 . Filtering of variants for novelty was performed by comparison to dbSNP131 and 1000 Genomes Project pilot SNP calls (March 2010).
Gene identification strategy and results. Analogous gene identification strategies were employed for the output from both the NextGENe and KCL Linux pipelines. Removal of previously identified variants (NextGENe: dbSNP; KCL pipeline: dbSNP, 1000 Genomes Project and in-house exomes) and synonymous changes resulted in the identification of 9 and 11 genes, respectively, with homozygous sequence variants in both individuals (subjects 5.1 and 5.2) from the consanguineous kindred ( Supplementary Table 3 ). Of these genes, five were shared, and ten were identified by a single analysis pipeline. Differences between the two data sets can be attributed to alternative variant calling settings and algorithms and to the subtraction of in-house exome data in the KCL pipeline. The sequencing data for candidate genes identified in both analyses were then interrogated in the remaining two exomes (from subjects 2.1 and 4.1). For both data sets, a single gene, EPG5 (KIAA1632), was identified in which all affected individuals had two truncating mutations in keeping with expected inheritance patterns ( Table 1) .
The homozygous sequence variants in subjects 5.1, 5.2 and 4.1 were present at read depths of 48, 52 and 113, respectively. The heterozygous variants in subject 2.1, c.2413-2A>G and c.6724delA, were present in reference to variant read depth ratios of 35:22 and 68:50, respectively. Sanger sequencing. All EPG5 mutations identified by exome sequencing were confirmed by bidirectional Sanger sequencing. Sequencing primers were designed to EPG5 (NM_020964.2), EI24 (NM_004879.3) and VMP1 (NM_030938.3) using Primer3 (see URLs) to cover all coding exons and intron-exon boundaries. PCR and sequencing reactions were performed as described previously 5 . Affected individuals without truncating mutations in EPG5 were subjected to sequencing of the human homologs of the Epg genes identified previously 10 , EI24 and VMP1. All sequencing primers used in this study are listed in Supplementary Table 4 .
Inheritance studies and mutation frequency in the general population. ABI traces for mutant alleles identified in families 1-13 are shown in Supplementary Figure 8 . Parental samples were available in 11 of the 13 families in which sequence variants were detected. In all cases, sequence variants exhibited segregation in accordance with autosomal recessive inheritance. Missense variants identified in subjects 6.1 and 12.1 segregated on the opposite allele to the truncating mutations identified in these families ( Supplementary  Fig. 8) . Additionally, unaffected siblings were available for segregation analysis in families 5 and 9 and were shown to have genotypes consistent with the expected inheritance pattern. Using Merlin (see URLs), we calculated an LOD score of 8.304 across all families (assuming a recessive model with full penetrance and no phenocopies, a marker allele frequency of 0.000444444 and a disease frequency of 0.00001).
Sequence variant in silico analysis and control chromosome studies. The missense variants, p.Leu457Pro and p.Gln784Pro, identified in subject 6.1 were subjected to in silico analysis using the Alamut software suite (see URLs). The affected amino acids showed moderate and low levels of conservation, respectively, with Grantham distances of 98 and 76. The SIFT and Align GVGD prediction tools indicated that neither change was likely to be disease causing, but PolyPhen-2 predicted that both changes were probably damaging. Neither variant was predicted to cause aberrant splicing. Both variants were absent from 374 in-house control chromosomes and from more than 9,000 chromosomes on the Exome Variant Server (see URLs). It is therefore unclear whether either or both of these variants are responsible for the presumed loss of function of this allele found in trans with the mutation encoding the p.Cys1945* alteration identified in this subject. Undetected mutations, such as large deletions, duplications, inversions, deep intronic splice-site mutations or promoter mutations in cis with these missense variants cannot be eliminated as the true causative change on this allele.
The p.Cys2038Arg missense variant identified in subject 12.1 was subjected to in silico analysis in the same manner. Cys2038 is highly conserved (from Drosophila melanogaster). The cysteine-to-arginine Grantham distance is 180. PolyPhen-2 and SIFT predicted that the change affected protein function, although, conversely, Align GVGD predicted that the change was unlikely to be pathogenic. This amino-acid change is absent from the Exome Variant Server, although an amino-acid change at the same location (p.Cys2038Gly) has been observed with a frequency of 1 in 9,990 alleles. Other mutations on this allele that are undetectable by sequencing of coding regions cannot be eliminated, but the high degree of conservation and the disruption of a cysteine residue, residues that are often involved in protein domain structure, indicate that this variant may be the second disease-causing alteration in this subject.
Sequence variants affecting canonical splice donor and acceptor sites were observed in four families (families 2-4 and 10) and were predicted to abolish splicing, according to the prediction tools in Alamut, namely npg SpliceSiteFinder-like, MaxEntScan, NNSPLICE and Human Splicing Finder. The homozygous variant c.1007A>G (p.Gln336Arg) detected in subject 7 affects the penultimate base of exon 2 and was predicted by SpliceSiteFinderlike and NNSPLICE to abolish the donor splice site; scores for MaxEntScan and Human Splicing Finder also indicated reduced splicing. Additionally, this variant was absent from the Exome Variant Server data set. This variant therefore seems highly likely to be the pathogenic mutation in this subject.
Quantitative fluorescent PCR. QF-PCR was used to interrogate exon copy number in subject 14.1. PCR was performed using a two-stage reaction with fluorescently labeled primers complementary to a tag sequence incorporated into the exon-specific primers in a multiplex reaction (full details are available upon request) 51 .
cDNA sequencing. Nested PCR primers flanking exon 28 of EPG5 were designed using Primer3. RNA was extracted from fibroblast culture from subject 4.1 using the RNeasy kit (Qiagen NV) and reverse transcribed using SuperScript III First-Strand Synthesis SuperMix (Life Technologies) with oligo(dT) primer. The resulting cDNA was subjected to two-stage nested PCR and sequenced. PCR and sequencing reactions were performed as described previously 5 .
Quantitative RT-PCR. qPCR was used to interrogate relative transcript abundance in subject 4.1. Dual-labeled probes and primers were designed for EPG5 and ACTB using the IDT RT-PCR assay design tool (see URLs). qPCR reactions were carried out using TaqMan Gene Expression Master Mix in a 25-µl reaction on an ABI 7900 instrument (Life Technologies). Analysis was conducted using the ∆∆C T method (according to the Applied Biosystems protocol Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR).
Immunostaining and confocal microscopy. Skeletal muscle sections were lightly fixed in 4% paraformaldehyde, permeabilized in 0.05% Tween-20 in PBS and blocked in 10% goat serum in PBS. Sections were immunostained using antibodies against SQSTM1 (Abcam, ab56416), NBR1 (Abcam, ab55474) and MURF2 (Abcam, ab4387) and counterstained with an affinity-purified rabbit polyclonal antibody against M-band titin (T-M8ra) 52 using standard procedures 53 . Fibroblasts were cultured for the times indicated, washed briefly in PBS and fixed in methanol for 10 min at −20 °C. Cells were immunostained using antibodies against SQSTM, NBR1 (Novus Biologicals, NBP1-71703), LAMP1 (monoclonal H4A3, Abcam, ab25630) and LC3B (Cell Signaling Technology, 2775S). Fluorescent secondary antibodies were from Jackson Immunoresearch and Molecular Probes. Specimens were analyzed by confocal microscopy using a Zeiss LSM-510 Meta microscope with 63× magnification and 2-4× zoom, and identical gain settings were used for image recording for all related samples.
Cell culture studies and protein blotting. Fibroblast cultures were maintained in DMEM supplemented with 10% FBS, 2 mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 50 µg/ml uridine in 3-or 10-cm culture dishes in an atmosphere with 5% CO 2 . Cells were treated with 100 nM rapamycin and/or 200 nM bafilomycin for 5-12 h before lysis or received equal concentrations of vehicle (DMSO). Cells were harvested after washing twice with PBS by direct addition of Laemmli sample buffer, and lysates were separated by 10-15% SDS-PAGE. Protein loading was normalized to actin staining and GAPDH immunoreactivity in protein blots. Protein blots were performed using standard procedures 53 , and antibodies to LC3B (Cell Signaling Technology), NBR1 (Abcam) and SQSTM1 (Abcam). All antibodies to phosphorylated proteins and pan antibodies (AKT, FOXO, GSK-3β, mTOR and p70S6K) were obtained from Cell Signaling Technology. The catalog numbers for the antibodies used were as follows: AKT (P-S473 AKT, 4060; P-T308 AKT, 2965; pan AKT, 4691); FOXO (P-Thr24 FOXO1/Thr32 FOXO3a, 9464; P-S253 FOXO3a, 9466; P-S318/321 FOXO3a, 9465; pan FOXO3a, 9467); GSK-3β (P-S9 GSK-3β, 9322; pan GSK-3β, 9315); mTOR (P-S2481 mTOR, 2974; P-S2448 mTOR, 2971; pan mTOR, 2983); and p70S6K (P-T389 p70S6K, 9234; pan p70S6K, 2708). Densitometric quantification was carried out as previously described 29 .
